Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

Summary

The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).

Timeline

Start

2013-12

Primary completion

2019-07

Completion

2019-12

Drugs

Indications